- Report
- June 2026
- 190 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- January 2026
- 180 Pages
Global
From €4037EUR$4,500USD£3,449GBP
- Report
- August 2026
- 553 Pages
Global
From €5249EUR$5,850USD£4,483GBP
- Report
- January 2026
- 280 Pages
Global
From €3241EUR$3,613USD£2,768GBP
€3813EUR$4,250USD£3,257GBP
- Report
- May 2026
- 157 Pages
Global
From €3544EUR$3,950USD£3,027GBP
- Report
- September 2025
- 393 Pages
Global
From €5271EUR$6,080USD£4,350GBP
- Report
- May 2026
- 356 Pages
Global
From €4306EUR$4,799USD£3,678GBP
- Report
- October 2025
- 573 Pages
Global
From €6415EUR$7,150USD£5,480GBP
- Report
- August 2025
- 495 Pages
Global
From €4441EUR$4,950USD£3,794GBP
- Report
- December 2025
- 481 Pages
Global
From €4306EUR$4,799USD£3,678GBP
- Report
- September 2025
- 180 Pages
Global
From €5338EUR$5,950USD£4,560GBP
- Report
- November 2025
- 192 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- July 2026
- 180 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- July 2026
- 188 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- July 2026
- 193 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- July 2026
- 180 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- July 2026
- 186 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- June 2026
- 193 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- January 2026
- 191 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- October 2025
- 100 Pages
Global
From €4396EUR$4,900USD£3,755GBP

Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more